Table 1.
Clinical manifestations of SLE patients according to Wnt5a protein status
| Clinical manifestations | Wnt5ap+ (n = 92) | Wnt5ap− (n = 23) | p-value | Wnt5au+ (n = 100) | Wnt5au− (n = 28) | p-value |
|---|---|---|---|---|---|---|
| Serositis (n, %) | 26 (28.3%) | 1 (4.3%) | 0.000 | 19 (19.0%) | 2 (7.1%) | 0.000 |
| Renal disorder (n, %) | 45 (48.9%) | 10 (43.5%) | 0.641 | 56 (56.0%) | 14 (50.0%) | 0.573 |
| Musculoskeletal (n, %) | 40 (43.5%) | 10 (43.5%) | 1.000 | 44 (44.0%) | 11 (39.3%) | 0.656 |
| Hematological (n, %) | 90 (97.8%) | 21 (91.3%) | 0.127 | 93 (93.0%) | 26 (92.9%) | 0.979 |
| Neuropsychiatric (n, %) | 22 (23.9%) | 5 (21.7%) | 0.826 | 22 (22.0%) | 7 (25.0%) | 0.737 |
| Cutaneous (n, %) | 65 (70.6%) | 11 (47.8%) | 0.038 | 73 (73.0%) | 12 (42.9%) | 0.003 |
Wnt5ap+, plasma-positive Wnt5a protein; Wnt5ap−, plasma-negative Wnt5a protein; Wnt5au+, urine-positive Wnt5a protein; Wnt5au−, urine-negative Wnt5a protein